Skip to main content

Table 3 Lifetime cost, life year (LY), quality-adjusted life year (QALY) and incremental cost-effectiveness ratio (ICER): Base-case analysis (patients aged 56 years)

From: Cost-utility analysis of biologic disease-modifying antirheumatic drugs (bDMARDs), targeted synthetic DMARDs (tsDMARDs) and biosimilar DMARDs (bsDMARDs) combined with methotrexate for Thai rheumatoid arthritis patients with high disease activity

Base-casea

Treatment optionsc

SoC

ETA

IFX

GOL

TCZ

RTX

TOF

BAR

bsIFXr

bsIFXi

bsADA

bsRTX

Discounted lifetime costsb

246728

1235188

1871581

2343472

1141704

1132732

1047153

1032029

1149523

797714

1013749

897446

Life year

6.52

6.94

6.77

6.87

6.87

6.93

6.91

6.93

6.84

6.81

6.82

6.62

Discounted Life yearsb

5.61

5.97

5.82

5.91

5.90

5.96

5.94

5.96

5.88

5.85

5.86

5.70

QALYs

5.59

5.98

5.83

5.95

5.94

5.99

5.92

5.97

5.92

5.88

5.88

5.70

Discounted QALYsb

4.80

5.14

5.00

5.11

5.10

5.14

5.09

5.12

5.08

5.05

5.05

4.90

Incremental costsb

 

988460

1624853

2096744

894976

886004

800425

785300

902795

550986

767021

650718

Incremental life yearsb

 

0.36

0.21

0.30

0.29

0.35

0.33

0.35

0.27

0.24

0.25

0.09

Incremental QALYsb

 

0.33

0.20

0.30

0.29

0.33

0.29

0.32

0.28

0.24

0.25

0.09

ICER (THB/QALY gained)b

 

2951501

8114427

6894610

3063318

2648855

2805366

2445862

3267273

2276729

3105650

7036061

  1. SoC Standard of care, bs biosimilar, ETA Etanercept (Enbrel®), IFX Infliximab (Remicade®), GOL Golimumab (Simponi®), TCZ Tocilizumab (Actemra®), RTX Rituximab (Mabthera®), TOF Tofacitinib (Xeljanz®), BAR Baricitinib (Olumiant®), bsIFXr Biosimilar infliximab (Remsima®), bsIFXi Biosimilar infliximab (Ixifi®), bsADA Biosimilar adalimumab (Amgevita®), bsRTX Biosimilar rituximab (Truxima®)
  2. aThe average values were obtained using a probabilistic model with 5,000 iterations
  3. bDiscounted by 3% annually
  4. cAll treatments were combined with methotrexate